Gordon Watkins Douglas researched cervical cancer, breach delivery, and treatment of high blood pressure during pregnancy in the US during the twentieth century. He worked primarily at Bellevue Hospital Center in New York, New York. While at Bellevue, he worked with William E. Studdiford to develop treatments for women who contracted infections as a result of illegal abortions performed throughout the US in unsterile environments. Douglas also established the first contraception and pregnancy termination clinic at Bellevue Hospital shortly after the legalization of abortion as a result of the 1973 US Supreme Court ruling in Roe v. Wade. Furthermore, Douglas showed that fetal and maternal cells exchange between the pregnant woman and fetus during pregnancy, which led to the later development of non-invasive prenatal testing in the early twenty-first century.

Charles Robert Cantor helped sequence the human genome, and he developed methods to non-invasively determine the genes in human fetuses. Cantor worked in the US during the twentieth and twenty-first centuries. His early research focused on oligonucleotides, small molecules of DNA or RNA. That research enabled the development of a technique that Cantor subsequently used to describe nucleotide sequences of DNA, a process called sequencing, in humans. Cantor was the principal scientist for the Human Genome Project, for which scientists sequenced the entirety of the human genome in 2003. Afterwards, Cantor became the chief scientific officer for Sequenom Inc., a company that provided non-invasive prenatal genetic testing. Such tests use a pregnant woman's blood to identify genetic mutations in a fetus during the first trimester of pregnancy.

Dennis Lo, also called Yuk Ming Dennis Lo, is a professor at the Chinese University of Hong Kong in Hong Kong, China. In 1997, Lo discovered fetal DNA in maternal plasma, which is the liquid component of a pregnant woman's blood. By 2002, Lo distinguished the DNA differences between pregnant women and their fetuses, enabling scientists to identify fetal DNA in pregnant women's blood. Lo used his discoveries to develop several non-invasive and prenatal genetic tests, including tests for blood group status and Trisomy 21, also called Down's Syndrome. Lo's discovery of fetal DNA in maternal plasma lessened the risks to pregnant women and fetuses during prenatal testing, and it enabled early identification of potential genetic mutations in developing fetuses.

In 2004, a team of researchers at Tufts-New England Medical Center in Boston, Massachusetts, investigated the fetal cells that remained in the maternal blood stream after pregnancy. The results were published in Transfer of Fetal Cells with Multilineage Potential to Maternal Tissue. The team working on that research included Kiarash Khosrotehrani, Kirby L. Johnson, Dong Hyun Cha, Robert N. Salomon, and Diana W. Bianchi. The researchers reported that the fetal cells passed to a pregnant woman during pregnancy could develop into multiple cell types in her organs. They studied these differentiated fetal cells in a cohort of women fighting different diseases. The researchers found that the fetal cells in the women differentiated into different cell types under the influence of maternal tissues, and that those differentiated cells concentrated in the tissue surrounding diseased tissues. According to the team, this response could be a therapeutic response to the disease in the once pregnant woman. The research indicated the long lasting effects of pregnancy in a woman's body.

Theodora Colborn studied how chemicals affect organisms as they develop and reproduce during the twentieth and twenty first centuries in the US. By the 1940s, researchers had reported that chemicals from agricultural and industrial processes affected how wild organisms developed, but in 1991, Colborn organized the Wingspread Conference in Racine, Wisconsin, at which a group of scientists classed these chemicals as environmentally harmful substances. Colborn and her colleagues called those chemicals endocrine disruptors, as they mimic or block the body's endocrine system. After scientists identified these chimicals and showed that they harm humans and wildlife, US Congress passed several acts to regulate these chemicals and to protect both wildlife and humans from their harmful effects.

Diethylstilbestrol (DES) is an artificially created hormone first synthesized in the late 1930s. Doctors widely prescribed DES first to pregnant women to prevent miscarriages, and later as an emergency contraceptive pill and to treat breast cancer. However, in 1971, physicians showed a link between DES and vaginal cancer during puberty in the children of women who had taken DES while pregnant. Consequently, the US Food and Drug Administration (FDA) banned its use during pregnancy. In the late 2000s, several studies showed that the grandchildren of women who had consumed DES also suffered medical issues. By the early decades of the twenty-first century, roughly ten million people in the US had been exposed to DES, and three generations of individuals had suffered medical issues due to DES exposure. Researchers class DES as an endocrine disruptor, which affects the form and function of the hormone (endocrine) system.

Diana W. Bianchi studied the medical treatment of premature and newborn infants in the US during the twentieth and twenty-first centuries. Bianchi helped develop non-invasive prenatal genetic tests that use cell-free fetal DNA found within maternal blood to diagnose genetic abnormalities of the fetus during pregnancy. The test provides a means to test fetuses for chromosomal and genetic abnormalities.

Published in 1971, Adenocarcinoma of the Vagina: Association of Maternal Stilbestrol Therapy with Tumor Appearance in Young Women, by Arthurs L. Herbst and colleagues, was the first piece of literature connecting maternal use of the drug diethylstilbestrol (DES), also called stilbestrol, with the development of a rare and severe form of vaginal cancer in young women. Diethylstilbestrol was later classified as an endocrine disruptor, a substance that disrupts the hormonal function of the body in those exposed to it during development or later in life. After Herbst and his team established the connection between DES and the occurrence of breast cancer, cervical cancer, infertility, and reproductive abnormalities, the US federal government banned use the drug for pregnant women. The article was published in the New England Journal of Medicine.

Sindell v. Abbott Laboratories was a 1980 California case that established the doctrine of market share liability for personal injury cases. For such liability, when a drug causes personal injury and the manufacturer of the drug cannot be identified, each producer is responsible for paying the settlement in proportion to the percentage of the market they supplied. Judith Sindell and Maureen Rogers brought the case against the producers of diethylstilbestrol (DES), which their mothers had taken during pregnancy to prevent miscarriage and other complications. Sindell and Rogers alleged that their mothers' ingestions of DES during pregnancy later caused Sindell and Rogers to develop cancers at the onset of puberty, but they could not identify the specific manufacturer of the drug. The market share liability ruling in Sindell allowed millions of DES-affected individuals to seek restitution for reproductive cancers caused by prenatal exposure to DES.

In 1996, the US Congress mandated that the US Environmental Protection Agency (EPA) create and regulate the Endocrine Disruptor Screening Program. The program tests industrial and agricultural chemicals for hormonal impacts in humans and in wildlife that may disrupt organisms' endocrine systems. The endocrine system regulates the release of small amounts of chemical substances called hormones to keep the body functioning normally. Some chemicals can impede the endocrine system's function by mimicking or blocking hormone reception, which can disrupt processes of development and reproduction and harm organisms. As of 2017, the Endocrine Disruptor Screening Program is the largest US program to identify and regulate chemicals that affect the normal production of sex hormones like estrogen and androgen, which can have long-term effects on development and reproduction.